Estimation of the Prevalence of Microcirculatory Dysfunction in Uremic Cardiopathy Among Dialysis… (NCT07608679) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Estimation of the Prevalence of Microcirculatory Dysfunction in Uremic Cardiopathy Among Dialysis Patients
France30 participantsStarted 2027-09
Plain-language summary
Patients with end-stage renal disease have a high burden of cardiovascular mortality, yet ischemic heart disease is often asymptomatic and difficult to diagnose in this population. Recent data suggest that microvascular coronary dysfunction may contribute significantly to myocardial ischemia in dialysis patients, but its true prevalence remains unknown. This study aims to evaluate microcirculatory coronary impairment in hemodialysis patients using invasive coronary angiography with measurement of coronary flow reserve (CFR), index of microcirculatory resistance (IMR). The study will also describe the clinical and biological characteristics associated with microvascular dysfunction in this population, in order to better understand the mechanisms of uremic cardiomyopathy and improve cardiovascular risk stratification.
Who can participate
Age range
18 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years
* Patients who have been on haemodialysis for at least 6 months
* Elevated troponin levels \> 40 ng/L in a sample taken whilst the patient was in a stable condition, dated within the last 3 months
* Patients capable of understanding the protocol and who have given their written informed consent to participate in the research
* Patients registered with the National Health Service or eligible for it
Exclusion Criteria:
* Age \> 90 years
* Patient undergoing daily home haemodialysis
* Symptomatic stage 3 or 4 peripheral arterial disease
* Severe hypertrophic cardiomyopathy (genetic or amyloid)
* Severe valvular heart disease leading to left ventricular remodelling (surgically contraindicated severe aortic stenosis, severe mitral regurgitation, severe aortic regurgitation)
* Hospitalisation for decompensation/acute heart failure within the last month
* Acute coronary syndrome and any coronary artery disease requiring angioplasty and/or stent implantation within the last 3 months
* Contraindication to METHERGIN and DOBUTAMINE
* Patients participating in another clinical research protocol that may affect the research objectives
* Patients already included in the study
* Patients under guardianship, curatorship or deprived of their liberty
* Patients under an activated future protection order
* Patients under family authorisation
* Patient under judicial protection
* Pregnant patient
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Percentage of patients with microcirculatory heart disease (i.e. microvascular dysfunction or microvascular vasospasm) identified during coronary angiography
Timeframe: Cardiac examinations to be carried out within 8 to 10 weeks of enrolment